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a b s t r a c t
Three ureido-pyrimidone derivatives (N-LH) were used to generate in combination with four dinuclear
arene ruthenium clips, (p-cymene)2Ru2(OO∩OO)Cl2 (OO∩OO ¼ oxalato, 2,5-dioxido-1,4-benzoquinonato,
2,5-dichloro-1,4-benzoquinonato, 5,8-dioxido-1,4-naphtoquinonato), twelve cationic arene ruthenium
metalla-cycles of the general formula [(p-cymene)2Ru2(OO∩OO)(N-LH)2]2(CF3SO3)4. The ureido-
pyrimidone moieties are able to form strong hydrogen-bonds by self-pairing, thus giving rise to
dimeric structures in solution. In addition, to better understand the behavior of the tetranuclear metalla-
cycles in solution, the neutral dinuclear arene ruthenium ureido-pyrimidone complexes of the general
formula {(p-cymene)RuCl2(N-L
H)}2 were also prepared and characterized. All metalla-assemblies were
studied in solution by NMR spectroscopy, conﬁrming the high stability of the metalla-cycles and the
usefulness of hydrogen-bonds in constructing supramolecular assemblies.
1. Introduction
Hydrogen-bonds have a very important role to play in the
structure and function of biological systems. Double strands in DNA
are held together by p-stacking interactions and by hydrogen-
bonds between complementary nucleotide Watson-Crick base
pairs, which overall give rise to the stable double helical structure
of DNA [1]. Similar to the DNA base pairing, the well-deﬁned
through-space directionality and hence high selectivity of H-
bonds have been used by many researchers to construct supra-
molecular assemblies [2]. Studies have shown that H-bonds could
be made stronger and/or more selective by introducing arrays of
donor (D) and acceptor (A) sites. These H-bonded systems are built
by the use of parallel arrays of H-bonds and they feature two or
more contiguous H-bonds on a heterocyclic scaffold. Units con-
sisting of up to six consecutive H-bonds have been reported [3], but
those constituted of triple [4] and quadruple [5] units are the most
common derivatives in molecular recognition and self-assembly
processes. It was also found that the arrangements of the D and A
sites, as well as the solvent in which the complexes are formed, are
crucial factors for the strength of the H-bond system [6].
Among the six possible permutations within quadruple H-
bonding systems, only three have been studied extensively: ADAD-
DADA, AADD-DDAA, ADDA-DAAD. Different scaffolds have been
used in designing and building up quadruple H-bonding self-
assembled systems, but the most popular one remains the 2-
ureido-4-[1H]-pyrimidinone (UPy) scaffold (Fig. 1). Upy dimers,
with a DDAA H-bond array, show high dimerization constants
(Kdim > 107 M1) and they can be readily synthesized [7]. The high
dimerization constant of UPy arises from limited repulsive sec-
ondary interactions and attractive secondary interactions within
the motif, as well as an intramolecular H-bond that creates order
within the molecule by prearrangement of the DDAA motif.
Coordination chemistry is also frequently used to generate su-
pramolecular assemblies [8]. The multivalency and directional
ability of metal centers have allowed the construction of two- and
three-dimensional assemblies. Among metal centers, the arene
ruthenium unit has received considerable attention [9]. The pres-
ence of the arene ligand, which occupies three adjacent coordina-
tion sites, facilitates the design and formation of discrete metalla-
assemblies. Combinations of arene ruthenium units with biden-
tate ligands [10], tridentate ligands [11], tetradentate ligands [12],
hexadentate ligands [13], mixtures of bidentate and tridentate [14],
bidentate and tetradentate [15], or tridentate and tetradentate li-
gands [16], have all generated arene ruthenium metalla-cycles and
metalla-assemblies. However, we have recently shown that a
combination of tetradentate and monodentate ligands can also be
successful in making metalla-cycles (Fig. 2), if a series of hydrogen-
bonds are involved between two monodentate ligands [17]. In this* Corresponding author.
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which should be used for any reference to this work
system, the dimeric structure of the two quadruple H-bonding
units mimics a bidentate ligand, thus offering new synthetic stra-
tegies for the generation of arene ruthenium metalla-assemblies.
This strategy has now been extended to two other ureido-
pyrimidone derivatives, and three additional tetradentate ligands,
thus overall generating twelve tetranuclear arene ruthenium
metalla-cycles (including the previously published metalla-cycle
4b). All metalla-cycles were studied by spectroscopic and spectro-
metric methods, and the results were compared to those obtained
for the previously published metalla-cycle [(p-cymene)2R-
u2(OO∩OO)(N-LHa)2]2(CF3SO3)4 (OO∩OO ¼ 2,5-dioxido-1,4-
benzoquinonato; N-LHa ¼ 1-(4-oxo-6-undecyl-1,4-
dihydropyrimidin-2-yl)-3-(pyridine-4-ylmethyl)urea). Overall,
this study conﬁrms the stability, versatility and usefulness of
hydrogen-bonds in coordination-driven self-assembly.
2. Results and discussion
Following the synthetic strategy developed by Marshall and de
Mendoza for 1-(4-oxo-6-undecyl-1,4-dihydropyrimidin-2-yl)-3-
(pyridin-4-ylmethyl) urea (N-LHa) [18], we have synthesized two
additional ureido-pyrimidone derivatives, by replacing at the
beginning of the synthetic route the starting material 4-(amino-
methyl)pyridine in N-LHa with respectively 4-(1-aminoethyl)
pyridine (for N-LHb) and 4-(2-aminoethyl)pyridine (for N-LHc)
(Fig. 3). Like the N-LHa parent compound, these two derivatives
show a dimeric structure in CDCl3 solution, which is conﬁrmed by
NMR spectroscopy.
Exploiting the dimeric nature of the N-LH ligands [17], a series of
dinuclear arene ruthenium complexes were prepared by reacting
{(p-cymene)RuCl2}2 with N-LH. The dinuclear complexes {(p-cym-
ene)RuCl2(N-LH)}2 (1e3) were obtained in excellent yields and
isolated as red-orange solids (Fig. 4). In the electro-spray ionization
mass spectra of 1e3 (chloroform/acetonitrile, positivemode), peaks
corresponding to [M  Cl]þ (M ¼ {(p-cymene)RuCl2(N-LH)}2) are
observed at m/z ¼ 1375.1 D for 1 and 1403.2 D for 2 and 3. A dif-
ference of 28 D between these peaks is consistent with the pro-
posed dimeric structures of 1e3, as the molecular weight of the N-
LHa and N-LHb (or N-LHc) derivatives only differs by 14 D (a carbon
and two hydrogens).
In the 1H NMR spectra of 1e3, the coordination of the dichloro
arene ruthenium units to the dimeric N-LH compounds only alters
the chemical shift of the pyridyl protons in the ortho-position of the
N-LH ligands. As emphasized in Fig. 5, the signal of the ortho-pyridyl
protons (H1) is shifted downﬁeld by approximately 0.4 ppm, while
all other signals of the N-LH ligands remain unchanged. Otherwise,
the presence of additional signals corresponding to the p-cymene
ligands is the only difference between the spectra of N-LHa and the
complex {(p-cymene)RuCl2(N-LHa)}2 (Fig. 5).
Then, the dinuclear arene ruthenium complexes 1e3 were
reacted in dichloromethane with oxalic acid, in the presence of
silver triﬂate, in view to obtain the tetranuclear arene ruthenium
metalla-cycles [(p-cymene)2Ru2(OO∩OO)(N-LH)2]2(CF3SO3)4
(4ae6a). However, under these conditions, the formation of the
desired metalla-cycle did not occur: only insoluble materials being
recovered after workup. Therefore, we used instead the following
strategy to generate the tetranuclear metalla-cycles 4ae6d: Addi-
tion of the dinuclear arene ruthenium clips, (p-cymene)2R-
u2(OO∩OO)Cl2 (OO∩OO ¼ oxalato, 2,5-dioxido-1,4-
benzoquinonato, 2,5-dichloro-1,4-benzoquinonato, 5,8-dioxido-
1,4-naphtoquinonato), to N-LH in the presence of silver triﬂate (see
experimental part). The twelve arene rutheniummetalla-cycles are
presented in Fig. 6.
Upon formation of the tetranuclear complexes 4ae6d, alike the
dinuclear arene ruthenium complexes 1e3, the 1H NMR signals of
the N-LH spacers are almost unaffected. Only the pyridyl protons



















Fig. 1. Dimeric structure of a quadruple 2-ureido-4-[1H]-pyrimidinone (UPy) scaffold.
Fig. 2. Arene ruthenium metalla-assemblies obtained from a combination of H-bond interactions and tetradentate and monodentate ligands [17].
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Whilst all the ortho-protons of the pyridyl groups are shifted
downﬁeld, the broadening of the pyridyl signals is only seldom
observed. Such broadening is not surprising considering that the
adjacent pyridyl units lose some of their rotational freedom as they
coordinate themetal centers and form themetalla-cycles. The same
behavior has been previously observed in analogous OO∩OO-
bridged arene ruthenium metalla-cycles incorporating bis-pyridyl
linkers [19]. The formation of the metalla-cycles 4ae6d is also
conﬁrmed by electro-spray ionization mass spectrometry. In all
cases, a dicationic peak corresponding to the intact tetracationic
metalla-cycle [(p-cymene)2Ru2(OO∩OO)(N-LH)2]24þ plus two triﬂate
anions ([M-2OTf]2þ) is observed (see experimental part).
Diffusion-ordered NMR spectroscopy (DOSY) was used to esti-
mate the hydrodynamic volumes of the complexes in solution and
to conﬁrm the formation of discrete and stable metalla-cycles. All
complexes show a single diffusion coefﬁcient, indicative of the
presence of single species in solution. The diffusion coefﬁcients (D)
of the dinuclear complexes 1e3 are comprised between 4  1010
and 5 1010 m2 s1 (Fig. 7A). Similarly, the diffusion coefﬁcients of
the tetranuclear metalla-cycles show values around
4.5  1010 m2 s1, and as emphasized in Fig. 7B for one repre-
sentative (4b) of these metalla-cycles, these values are smaller than
those observed for the dimeric N-LH systems
(D¼ 7.5 1010 m2 s1). This difference in theD values is consistent
with the difference in sizes between the N-LH dimers and the tet-
ranuclear metalla-cycles, the size being inversely related to D.
3. Conclusion
Several cationic arene ruthenium metalla-cycles were synthe-
sized and characterized, showing the versatility of hydrogen-bonds
in designing supramolecular assemblies. The DDAA hydrogen-bond
array present in the ureido-pyrimidone dimers remained stable in
solution, even after coordination to the arene ruthenium centers.
The synthetic strategy used in this work can be applied to other
systems, thus paving the way for the preparation of more elaborate
arene ruthenium metalla-assemblies.
4. Experimental section
4.1. Materials and methods
All chemicals were purchased from commercial sources and
used as received unless speciﬁed otherwise. The N-LHa ligand [18],



























































Fig. 4. Structures of the dinuclear arene ruthenium complexes {(p-cymene)RuCl2(N-LH)}2 (1e3).
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were prepared according to publishedmethods. The 1H and 13C{1H}
NMR spectra were recorded on a narrow-bore Bruker Avance II 400
(9.4 T) spectrometer using the residual protonated solvent as an
internal standard. The rf pulses in direct-excitation experiments
were set to 30 ﬂip angles, corresponding to 2.8 ms for an rf-ﬁeld
strength of 27 kHz, for both 1H and 13C channels. The recycling
delay used in all 1D spectra was 5 s. DOSY spectra utilized a
diffusion delay of 100 ms and a recycling delay of 1 s. Infrared
spectra were recorded as KBr pellets on a Perkin-Elmer FTIR
1720  spectrometer. Electrospray ionization mass spectra of the
complexes were obtained in positive ion mode on a Bruker FTMS
4.7T BioAPEX II mass spectrometer. UVevisible absorption spectra
were recorded in CH2Cl2 on a Perkin Elmer UVevisible spectro-
photometer at 105 M concentrations.
4.2. Synthesis of N-LHb
4-(1-Aminoethyl)pyridine (0.11 g, 0.91 mmol) and N-(6-oxo-4-
undecyl-1,6-dihydropyrimidin-2-yl)-1H-imidazole-1-carboxamide
(0.35 g, 1.00 mmol) were placed in a sealed tube containing dry
DMF (5 mL). To the solution, triethylamine (1.5 mL) was added and
the mixture was warmed to 70 C overnight. After cooling to rt, the
solvent was removed under vacuum and the residue was triturated
in methanol. The mixture was ﬁltered and the residue washed with
methanol, chloroform and ethyl acetate. N-LHb was obtained as a
white solid with a yield of 50% (0.19 g).
1H NMR (400 MHz, CDCl3, ppm): d ¼ 12.91 (s, 2H), 12.10 (s, 2H),
10.81 (d, 3JH-H ¼ 7.2 Hz, 2H), 8.52 (d, 3JH-H ¼ 6.0 Hz, 4H), 7.31 (m,
4H), 5.87 (s, 2H), 4.92 (quint, 3JH-H ¼ 7.0 Hz, 2H), 2.43 (t, 3JH-
H ¼ 7.7 Hz, 4H), 1.56e1.63 (m, 10H), 1.25e1.28 (m, 32H), 0.86 (t, 3JH-
H ¼ 6.4 Hz, 6H). 13C{1H} NMR (100 MHz, CDCl3, ppm): d ¼ 173.08;
156.10; 154.60; 153.40; 152.60; 150.09; 121.16; 106.12; 49.42;
32.71; 31.91; 29.58; 29.56; 29.42; 29.33; 29.15; 28.86; 26.96; 22.70;
21.98; 14.14. IR (KBr) (cm1) ¼ 1695 (s, NH), 1662 (s, NH), 1593 (s,
NH); 1265 (s, CN).
4.3. Synthesis of N-LHc
4-(2-Aminoethyl)pyridine (0.11 g, 0.91 mmol) and N-(6-oxo-4-
undecyl-1,6-dihydropyrimidin-2-yl)-1H-imidazole-1-carboxamide
(0.35 g, 1.00 mmol) were reacted following the procedure for N-LHb
in DMF (5 mL) and triethylamine (1.5 mL) at 70 C overnight. N-LHc
was obtained as a white solid with a yield of 72% (0.27 g).
1H NMR (400 MHz, CDCl3, ppm): d ¼ 13.02 (s, 2H), 11.91 (s, 2H),
10.42 (t, 3JH-H ¼ 5.4 Hz, 2H), 8.49 (d, 3JH-H ¼ 6.1 Hz, 4H), 7.18 (d, 3JH-
H ¼ 6.1 Hz, 4H), 5.81 (s, 2H), 3.54 (dt, 3JH-H ¼ 8.1 Hz, 4JH-H ¼ 6.1 Hz,
4H), 2.94 (t, 3JH-H ¼ 7.5 Hz, 4H), 2.47 (t, 3JH-H ¼ 7.7 Hz, 4H), 1.64
(quint, 3JH-H ¼ 7.6 Hz, 4H), 1.26e1.38 (m, 32H), 0.87 (t, 3JH-
H ¼ 6.5 Hz, 6H). 13C{1H} NMR (100 MHz, CDCl3, ppm): d ¼ 173.12;
156.66; 154.59; 152.66; 149.82; 148.09; 124.23; 105.91; 40.21;
34.97; 32.73; 31.91; 29.59; 29.58; 29.45; 29.33; 29.18; 28.87; 26.99;
22.77; 14.13. IR (KBr) (cm1) ¼ 1702 (s, NH), 1654 (s, NH), 1579 (s,
NH); 1256 (s, CN).
Fig. 5. 1H NMR spectra of complex 1 and N-LHa (400 MHz, CDCl3, 23 C).
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Fig. 6. Structures of the twelve tetranuclear arene ruthenium metalla-cycles [(p-cymene)2Ru2(OO∩OO)(N-LH)2]2(CF3SO3)4 (4ae6d).
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4.4. Synthesis of 1e3
A mixture of {(h6-arene)Ru(m2-Cl)Cl}2 (0.03 g, 0.06 mmol) and
N-LH (N-LHa, 0.04 g, 0.06 mmol; N-LHb, 0.05 g, 0.06 mmol; N-LHc,
0.05 g, 0.06 mmol) is stirred in CHCl3 (2 mL) at room temperature
for 16 h. Diethyl ether was added to precipitate the product, which
was isolated by ﬁltration and dried under vacuum.
1: Yield ¼ 98% (0.17 g). 1H NMR (400 MHz, CDCl3, ppm):
d ¼ 12.83 (s, 2H), 12.15 (s, 2H), 11.10 (s, 2H), 8.92 (d, 3JH-H ¼ 6.0 Hz,
4H), 7.30e7.33 (d, 3JH-H ¼ 5.8 Hz, 4H), 5.82 (s, 2H), 5.40 (d, 3JH-
H ¼ 5.8 Hz, 4H), 5.19 (d, 3JH-H ¼ 5.8 Hz, 4H), 4.46 (d, 3JH-H ¼ 5.7 Hz,
4H), 2.99 (sept, 3JH-H ¼ 6.9 Hz, 2H), 2.47 (t, 3JH-H ¼ 7.8 Hz, 4H), 2.10
(s, 6H), 1.63 (quint, 3JH-H ¼ 7.5 Hz, 4H), 1.23e1.36 (m, 44H), 0.87 (t,
3JH-H ¼ 6.8 Hz, 6H). 13C{1H} NMR (100 MHz, CDCl3, ppm):
d ¼ 194.92; 156.76; 154.60; 152.99; 123.17; 106.01; 103.60; 82.63;
82.35; 31.84; 30.61; 29.53; 29.41; 29.27; 29.10; 28.83; 26.88; 22.64;
22.27; 18.29; 14.09; 0.97. IR (KBr) (cm1) ¼ 3421 (br, NH); 1697 (s,
NH); 1660 (s, NH); 1587 (s, NH); 1257 (s, CN). MS (ESI(þ)) ¼ 1375.1
[MCl]þ. UVeVis (CH2Cl2, 1.0  105 M): lmax ¼ 408 nm
(ε ¼ 0.15  105 M1cm1).
2: Yield ¼ 93% (0.16 g). 1H NMR (400 MHz, CDCl3, ppm):
d ¼ 12.81 (s, 2H), 12.09 (s, 2H), 10.90 (d, 3JH-H ¼ 6.9 Hz, 2H), 8.90 (d,
3JH-H ¼ 5.7 Hz, 4H), 7.32 (d, 3JH-H ¼ 4.6 Hz, 4H), 5.84 (s, 2H), 5.39 (q,
3JH-H ¼ 5.4 Hz, 4H), 5.20 (q, 3JH-H ¼ 4.7 Hz, 4H), 4.91 (quint, 3JH-
H¼ 7.1 Hz, 2H), 3.00 (sept, 3JH-H¼ 7.1 Hz, 2H), 2.44 (t, 3JH-H¼ 7.8 Hz,
4H), 2.10 (s, 6H), 1.63 (quint, 3JH-H¼ 7.5 Hz, 4H), 1.23e1.30 (m, 44H),
0.86 (t, 3JH-H ¼ 6.6 Hz, 6H). 13C{1H} NMR (100 MHz, CDCl3, ppm):
d ¼ 173.01; 165.76; 155.92; 154.72; 154.34; 152.76; 122.18; 115.94;
106.04; 103.77; 96.75; 82.44; 82.33; 49.08; 32.63; 31.85; 30.58;
29.53; 29.39; 29.27; 29.10; 28.82; 26.83; 22.64; 22.23; 21.51; 18.21;
14.09. IR (KBr) (cm1) ¼ 3421 (br, NH); 1698 (s, NH); 1658 (s, NH);
1585 (s, NH); 1255 (s, CN). MS (ESI(þ)) ¼ 1403.2 [MCl]þ. UVeVis
(CH2Cl2, 1.0  105 M): lmax ¼ 409 nm (ε ¼ 0.18  105 M1cm1).
3: Yield ¼ 96% (0.17 g). 1H NMR (400 MHz, CDCl3, ppm):
d ¼ 12.91 (s, 2H), 11.86 (s, 2H), 10.41 (s, 2H), 8.85 (d, 3JH-H ¼ 5.7 Hz,
4H), 7.20 (d, 3JH-H ¼ 5.7 Hz, 4H), 5.79 (s, 2H), 5.40 (d, 3JH-H ¼ 5.7 Hz,
4H), 5.18 (d, 3JH-H ¼ 5.7 Hz, 4H), 3.53 (q, 3JH-H ¼ 6.5 Hz, 4H),
2.92e2.99 (m, 6H), 2.47 (t, 3JH-H ¼ 7.7 Hz, 4H), 2.04 (s, 6H), 1.66
(quint, 3JH-H ¼ 7.6 Hz, 4H), 1.24e1.37 (m, 44H), 0.86 (t, 3JH-
H ¼ 6.6 Hz, 6H). 13C{1H} NMR (100 MHz, CDCl3, ppm): d ¼ 173.12;
156.51; 154.36; 152.79; 150.66; 125.13; 105.80; 103.39; 96.96;
82.79; 82.14; 39.57; 34.27; 32.68; 32.85; 30.58; 29.53; 29.41; 29.27;
29.13; 28.86; 26.88; 22.64; 22.26; 18.17; 14.10. IR (KBr)
(cm1) ¼ 3425 (br, NH); 1698 (s, NH); 1659 (s, NH); 1586 (s, NH);
1255 (s, CN). MS (ESI(þ)) ¼ 1403.2 [MCl]þ. UVeVis (CH2Cl2,
1.0  105 M): lmax ¼ 402 nm (ε ¼ 0.18  105 M1cm1).
4.5. Synthesis of [4ae6d](CF3SO3)4
A mixture of 1 equiv. of (p-cymene)2Ru2(OO∩OO)Cl2 (0.04 g,
0.06 mmol) and 3 equiv. of AgCF3SO3 (0.04 g, 0.18 mmol) in CH2Cl2
(4 mL) was stirred at room temperature for 2 h and ﬁltered to
remove AgCl. Then N-LH (0.04 g, 0.06 mmol) was added to the
ﬁltrate and the solutionwas stirred at room temperature overnight.
The volume of the solvent was halved and diethyl ether was added
to precipitate [(p-cymene)2Ru2(OO∩OO)(N-LH)2]2(CF3SO3)4, which
was collected as dark solids by ﬁltration.
4a: Yield ¼ 38% (0.08 g). 1H NMR (400 MHz, CD3CN, ppm):
d ¼ 12.81 (s, 4H), 12.06 (s, 4H), 10.98 (s, 4H), 8.29e8.38 (m, 8H),
7.85e7.88 (m, 8H), 5.66e5.81 (m, 12H), 5.48e5.55 (m, 8H),
4.43e4.55 (m, 8H), 2.75e2.82 (m, 4H), 2.37e2.42 (m, 8H), 2.10 (s,
12H), 1.50e1.62 (m, 8H), 1.23e1.36 (m, 88H), 0.86 (t, 3JH-H ¼ 8.0 Hz,
12H). 13C{1H} NMR (100 MHz, CD3CN, ppm): d ¼ 172.81; 170.59;
156.73; 154.38; 153.35; 151.61; 151.56; 123.56; 122.67; 119.48;
105.33; 101.72; 97.36; 82.18; 81.58; 31.90; 31.63; 30.88; 29.34;
29.24; 29.20; 29.08; 28.95; 28.64; 26.56; 22.38; 21.55; 21.43; 21.37;
21.24; 17.23; 13.39. MS (ESI(þ)) ¼ 1507.1 [M  2 OTf]2þ. UVeVis
(CH2Cl2, 1.0 105 M): lmax¼ 383 nm (ε¼ 0.28 105M1 cm1). IR
(KBr) (cm1) ¼ 3067 (br, NH); 1698 (s, NH); 1661 (s, NH); 1589 (s,
NH); 1260 (s, CN).
4b: Yield ¼ 72% (0.12 g). 1H NMR (400 MHz, CD3CN, ppm):
d¼ 12.73 (s, 4H),11.98 (s, 4H),11.06 (t, 3JH-H¼ 6.0 Hz, 4H), 8.04e8.10
(m, 8H), 7.30e7.37 (m, 8H), 5.85e5.89 (m, 8H), 5.74 (s, 44H),
5.63e5.69 (m, 8H), 5.62 (s, 4H), 4.38 (d, 3JH-H ¼ 5.1 Hz, 8H), 2.82
(sept, 3JH-H ¼ 5.6 Hz, 4H), 2.44 (t, 3JH-H ¼ 8.0 Hz, 8H), 2.10 (s, 12H),
1.55e1.62 (m, 8H), 1.28e1.31 (m, 88H), 0.88 (t, 3JH-H ¼ 6.0 Hz, 12H).
13C{1H} NMR (100 MHz, CD3CN, ppm): d ¼ 183.53; 152.04; 128.57;
123.48; 122.43; 117.00; 83.08; 81.53; 31.66; 31.34; 30.79; 29.07;
28.96; 28.82; 28.69; 28.34; 26.23; 23.05; 22.11; 21.11; 16.99; 13.11.
MS (ESI(þ))¼ 1557.1 [M 2 OTf]2þ. UVeVis (CH2Cl2, 2.0 106 M):
lmax ¼ 299 nm (ε ¼ 3.64  105 M1 cm1), 496 nm
(ε¼ 3.39 105M1 cm1). IR (KBr) (cm1)¼ 3330 (br, NH); 1700 (s,
NH); 1659 (s, NH); 1521 (s, NH); 1257 (s, CN).
4c: Yield ¼ 72% (0.12 g). 1H NMR (400 MHz, CD3OD, ppm):
d ¼ 8.24 (d, 3JH-H ¼ 5.8 Hz, 8H), 7.44 (d, 3JH-H ¼ 6.0 Hz, 8H), 6.10 (d,
3JH-H ¼ 6.1 Hz, 8H), 5.91 (d, 3JH-H ¼ 6.4 Hz, 12H), 4.55 (s, 8H), 2.90
(sept, 3JH-H¼ 5.6 Hz, 4H), 2.48e2.53 (m, 8H), 2.24 (s,12H),1.62e1.71
(m, 8H), 1.28e1.38 (m, 88H), 0.87e0.90 (m, 12H). 13C{1H} NMR
(100 MHz, CD3OD, ppm): d ¼ 152.22; 145.84; 135.10; 128.84;
126.16; 122.66; 119.47; 117.30; 84.94; 83.21; 82.76; 79.88; 33.39;
31.65; 31.20; 29.34; 29.11; 23.33; 22.41; 21.52; 19.92; 13.43; 13.38.
MS (ESI(þ))¼ 1625.0 [M 2 OTf]2þ. UVeVis (CH2Cl2, 2.0 106M):
lmax ¼ 324 nm (ε ¼ 2.27  105 M1 cm1), 508 nm
(ε¼ 2.27 105M1 cm1). IR (KBr) (cm1)¼ 3430 (br, NH); 1707 (s,
Fig. 7. DOSY NMR spectra (CDCl3, 23 C) of complexes 1e3 (A), N-LHa and 4b (B).
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NH); 1658 (s, NH); 1498 (s, NH); 1255 (s, CN).
4d: Yield ¼ 23% (0.10 g). 1H NMR (400 MHz, CD3OD, ppm):
d ¼ 8.34 (d, 3JH-H ¼ 5.8 Hz, 8H), 7.32 (d, 3JH-H ¼ 6.1 Hz, 8H), 7.17 (s,
8H), 5.90 (s, 4H), 5.80 (d, 3JH-H ¼ 6.1 Hz, 8H), 5.57 (d, 3JH-H ¼ 6.1 Hz,
8H), 4.54 (s, 8H), 2.79 (sept, 3JH-H ¼ 4.8 Hz, 4H), 2.57 (quint, 3JH-
H¼ 6.9 Hz, 8H), 2.07 (s, 12H), 1.64e1.71 (m, 8H), 1.26e1.31 (m, 88H),
0.87 (t, 3JH-H ¼ 6.0 Hz, 12H). 13C{1H} NMR (100 MHz, CD3CN, ppm):
d ¼ 172.67; 170.71; 156.85; 154.31; 153.34; 151.64; 137.30; 125.87;
123.68; 122.68; 119.49; 111.38; 105.27; 103.32; 98.97; 83.88; 82.91;
41.42; 31.81; 31.65; 30.37; 29.29; 29.12; 28.83; 28.47; 26.36; 22.39;
21.27; 16.28; 13.40. MS (ESI(þ)) ¼ 1607.0 [M  2 OTf]2þ. UVeVis
(CH2Cl2, 3.6  106 M): lmax ¼ 306 nm (ε ¼ 2.38  105 M1 cm1),
434 nm (ε ¼ 1.66  105 M1 cm1), 639 nm
(ε ¼ 0.55  105 M1 cm1), 693 nm (ε ¼ 0.62  105 M1 cm1). IR
(KBr) (cm1) ¼ 3334 (br, NH); 1704 (s, NH); 1659 (s, NH); 1535 (s,
NH); 1274 (s, CN).
5a: Yield ¼ 21% (0.09 g). 1H NMR (400 MHz, CD3OD, ppm):
d ¼ 8.47 (d, 3JH-H ¼ 6.1 Hz, 8H), 7.55 (d, 3JH-H ¼ 6.0 Hz, 8H),
5.80e5.82 (m, 12H), 5.57 (d, 3JH-H ¼ 6.0 Hz, 8H), 2.86 (sept, 3JH-
H ¼ 6.4 Hz, 12H), 2.52e2.61 (m, 8H), 2.29 (s, 12H), 1.52e1.63 (m,
20H), 1.28e1.40 (m, 88H), 0.88e0.91 (m, 12H). 13C{1H} NMR
(100 MHz, CD3OD, ppm): d ¼ 154.25; 143.13; 125.92; 124.68;
123.38; 120.21; 103.59; 98.79; 83.79; 82.16; 81.18; 78.95; 33.07;
32.34; 30.73; 30.58; 30.48; 30.35; 30.04; 28.55; 23.74; 22.67;
22.65; 17.94; 14.46. MS (ESI(þ)) ¼ 1535.1 [M  2 OTf]2þ. UVeVis
(CH2Cl2,1.0 105 M): lmax¼ 387 nm (ε¼ 0.28 105M1 cm1). IR
(KBr) (cm1) ¼ 3276 (br, NH); 1660 (s, NH); 1633 (s, NH); 1242 (s,
CN).
5b: Yield ¼ 61% (0.12 g). 1H NMR (400 MHz, CD3OD, ppm):
d ¼ 8.21e8.26 (m, 8H), 7.44e7.49 (m, 8H), 5.93e6.00 (m, 12H),
5.74e5.79 (m, 12H), 2.86 (sept, 3JH-H ¼ 7.7 Hz, 4H), 2.47e2.53 (m,
4H), 2.17 (s, 12H), 1.52e1.66 (m, 20H), 1.29e1.35 (m, 88H),
0.87e0.91 (m, 12H). 13C{1H} NMR (100 MHz, CD3OD, ppm):
d ¼ 185.48; 185.37; 154.15; 153.91; 153.85; 126.52; 125.02; 123.35;
120.18; 117.01; 105.06; 105.01; 104.78; 102.66; 99.87; 99.67; 84.76;
84.69; 83.58; 83.31; 83.18; 33.10; 33.07; 32.55; 30.79; 30.75; 30.66;
30.52; 30.49; 30.42; 30.11; 28.49; 23.77; 22.56; 22.51; 21.72; 18.20;
18.15; 14.49. MS (ESI(þ)) ¼ 1585.1 [M  2 OTf]2þ. UVeVis (CH2Cl2,
2.2  106 M): lmax ¼ 298 nm (ε ¼ 3.42  105 M1 cm1), 496 nm
(ε¼ 3.07 105M1 cm1). IR (KBr) (cm1)¼ 3293 (br, NH); 1700 (s,
NH); 1658 (s, NH); 1523 (s, NH); 1257 (s, CN).
5c: Yield ¼ 57% (0.12 g). 1H NMR (400 MHz, CD3OD, ppm):
d ¼ 8.10e8.16 (m, 8H), 7.38e7.40 (m, 8H), 5.89e5.92 (m, 12H),
5.73e5.77 (m, 8H), 3.47e3.50 (m, 4H), 2.86 (sept, 3JH-H ¼ 6.0 Hz,
4H), 2.47e2.53 (m, 16H), 2.24 (s, 12H), 1.24e1.56 (m, 96H),
0.87e0.91 (m, 12H). 13C{1H} NMR (100 MHz, CD3OD, ppm):
d ¼ 179.07; 153.80; 125.84; 125.34; 123.34; 120.17; 105.42; 84.74;
83.97; 33.11; 32.71; 30.74; 30.55; 30.02; 28.50; 23.76; 22.52; 21.64;
21.39; 18.20; 14.49. MS (ESI(þ)) ¼ 1652.9 [M  2 OTf]2þ. UVeVis
(CH2Cl2, 2.3  106 M): lmax ¼ 325 nm (ε ¼ 2.31  105 M1 cm1),
506 nm (ε¼ 2.40 105M1 cm1). IR (KBr) (cm1)¼ 3336 (br, NH);
1704 (s, NH); 1658 (s, NH); 1497 (s, NH); 1256 (s, CN).
5d: Yield ¼ 21% (0.09 g). 1H NMR (400 MHz, CD3OD, ppm):
d¼ 8.38 (s, 8H), 7.40e7.44 (m, 8H), 7.15e7.18 (m, 8H), 5.81e5.89 (m,
12H), 5.56e5.59 (m, 12H), 2.79 (sept, 3JH-H ¼ 7.2 Hz, 4H), 2.46e2.52
(m, 8H), 2.07 (s, 12H), 1.46e1.63 (m, 20H), 1.26e1.36 (m, 88H),
0.86e0.91 (m, 12H). 13C{1H} NMR (100 MHz, CD3OD, ppm):
d ¼ 153.00; 138.56; 123.42; 123.03; 120.26; 104.86; 100.85; 85.73;
83.95; 33.12; 33.08; 31.98; 30.73; 30.59; 30.49; 30.06; 23.80; 22.45;
17.35; 14.52. MS (ESI(þ)) ¼ 1635.1 [M  2 OTf]2þ. UVeVis (CH2Cl2,
3.1  106 M): lmax ¼ 434 nm (ε ¼ 1.57  105 M1 cm1), 641 nm
(ε ¼ 0.51  105 M1 cm1), 693 nm (ε ¼ 0.51  105 M1 cm1). IR
(KBr) (cm1) ¼ 3286 (br, NH); 1703 (s, NH); 1659 (s, NH); 1532 (s,
NH); 1275 (s, CN).
6a: Yield ¼ 23% (0.09 g). 1H NMR (400 MHz, CD3OD, ppm):
d ¼ 8.41 (d, 3JH-H ¼ 5.8 Hz, 8H), 7.50 (d, 3JH-H ¼ 5.8 Hz, 8H), 6.10 (s,
4H), 5.80 (d, 3JH-H ¼ 5.9 Hz, 8H), 5.58 (d, 3JH-H ¼ 5.9 Hz, 8H), 3.58 (t,
3JH-H ¼ 6.6 Hz, 8H), 3.00 (t, 3JH-H ¼ 6.7 Hz, 8H), 2.84 (sept, 3JH-
H ¼ 6.9 Hz, 4H), 2.60 (t, 3JH-H ¼ 7.7 Hz, 8H), 2.13 (s, 12H), 1.64e1.68
(m, 8H), 1.28e1.40 (m, 88H), 0.90 (t, 3JH-H ¼ 6.9 Hz, 12H). 13C{1H}
NMR (100 MHz, CDCl3, ppm): d ¼ 166.16; 152.41; 127.65; 126.40;
118.76; 102.01; 97.31; 82.36; 80.46; 79.94; 77.48; 47.12; 46.90;
31.62; 29.28; 29.22; 29.14; 29.02; 28.93; 22.29; 21.19; 21.15; 16.50;
12.99. MS (ESI(þ)) ¼ 1535.1 [M  2 OTf]2þ. UVeVis (CH2Cl2,
1.0  105 M): lmax ¼ 383 nm (ε ¼ 0.26  105 M1 cm1). IR (KBr)
(cm1) ¼ 3338 (br, NH); 1706 (s, NH); 1657 (s, NH); 1632 (s, NH);
1258 (s, CN).
6b: Yield ¼ 65% (0.13 g). 1H NMR (400 MHz, CD3OD, ppm):
d ¼ 8.17 (d, 3JH-H ¼ 5.8 Hz, 8H), 7.38 (d, 3JH-H ¼ 5.7 Hz, 8H), 6.01 (d,
3JH-H ¼ 6.0 Hz, 4H), 5.79 (d, 3JH-H ¼ 6.1 Hz, 12H), 3.13e3.23 (m, 8H),
2.83e2.90 (m, 4H), 2.57 (t, 3JH-H¼ 7.6 Hz, 8H), 2.17 (s, 6H),1.66e1.72
(m, 8H), 1.28e1.36 (m, 96H), 0.90 (t, 3JH-H ¼ 6.5 Hz, 12H). 13C{1H}
NMR (100 MHz, CD3OD, ppm): d ¼ 153.78; 127.89; 123.44; 120.27;
84.79; 83.13; 33.11; 32.60; 30.79; 30.54; 23.78; 22.54; 14.49. MS
(ESI(þ)) ¼ 1585.1 [M  2 OTf]2þ. UVeVis (CH2Cl2, 2.2  106 M):
lmax ¼ 497 nm (ε ¼ 2.23  105 M1 cm1). IR (KBr) (cm1) ¼ 3421
(br, NH); 1524 (s, NH); 1257 (s, CN).
6c: Yield ¼ 53% (0.11 g). 1H NMR (400 MHz, CD3CN, ppm):
d ¼ 11.74 (s, 4H), 10.75 (s, 4H), 8.12 (d, 3JH-H ¼ 5.9 Hz, 8H), 7.30 (d,
3JH-H ¼ 5.8 Hz, 8H), 5.96 (d, 3JH-H ¼ 6.3 Hz, 8H), 5.76 (d, 3JH-
H ¼ 6.1 Hz, 8H), 5.58 (s, 4H), 3.06e3.15 (m, 8H), 2.87 (sept, 3JH-
H ¼ 6.9 Hz, 12H), 2.50 (t, 3JH-H ¼ 7.6 Hz, 8H), 2.10 (s, 12H); 1.64e1.66
(m, 8H); 1.29e1.38 (m, 88H), 0.90 (t, 3JH-H ¼ 6.5 Hz, 12H). 13C{1H}
NMR (100 MHz, CD3CN, ppm): d ¼ 152.23; 128.57; 126.27; 122.43;
119.24; 83.09; 82.04; 31.36; 30.94; 29.07; 28.81; 28.76; 28.20;
26.13; 22.11; 21.05; 13.12. MS (ESI(þ)) ¼ 1653.0 [M  2 OTf]2þ.
UVeVis (CH2Cl2, 2.1  105 M): lmax ¼ 326 nm
(ε ¼ 2.20  105 M1 cm1), 509 nm (ε ¼ 2.25  105 M1 cm1). IR
(KBr) (cm1) ¼ 3367 (br, NH); 1703 (s, NH); 1658 (s, NH); 1498 (s,
NH); 1225 (s, CN).
6d: Yield ¼ 46% (0.10 g). 1H NMR (400 MHz, CD2Cl2, ppm):
d ¼ 8.18 (d, 3JH-H ¼ 5.6 Hz, 8H), 7.23e7.25 (m, 8H), 7.15 (s, 8H), 5.60
(d, 3JH-H ¼ 6.1 Hz, 12H), 5.42 (d, 3JH-H ¼ 6.0 Hz, 12H), 3.30 (q, 3JH-
H ¼ 6.6 Hz, 4H), 2.80e2.87 (m, 4H), 2.77 (q, 3JH-H ¼ 6.7 Hz, 4H),
2.47e2.54 (m, 4H), 2.07 (s, 12H), 1.27e1.34 (m, 88H), 0.89 (t, 3JH-
H ¼ 6.5 Hz, 12H). 13C{1H} NMR (100 MHz, CD2Cl2, ppm): d ¼ 172.56;
171.51; 170.62; 156.24; 155.86; 154.50; 153.76; 153.00; 152.79;
152.21; 151.83; 151.65; 137.22; 136.83; 126.24; 126.05; 125.89;
122.70; 119.51; 112.23; 111.62; 105.18; 103.20; 103.03; 99.11; 98.31;
84.06; 83.70; 83.05; 82.76; 39.95; 34.45; 31.94; 31.71; 31.63; 30.40;
30.36; 29.42; 29.33; 29.23; 29.18; 29.15; 29.07; 29.01; 28.72; 28.46;
26.39; 22.45; 22.39; 21.29; 21.11; 16.30. MS (ESI(þ)) ¼ 1635.1
[M  2 OTf]2þ. UVeVis (CH2Cl2, 2.8  106 M): lmax ¼ 310 nm
(ε ¼ 2.56  105 M1 cm1), 435 nm (ε ¼ 1.83  105 M1 cm1),
644 nm (ε ¼ 0.55  105 M1 cm1), 696 nm
(ε¼ 0.58 105 M1 cm1). IR (KBr) (cm1)¼ 3336 (br, NH); 1710 (s,
NH); 1659 (s, NH); 1535 (s, NH); 1274 (s, CN).
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